Yersinia pestis causes plague, one of the deadliest infectious diseases in human history. The bacterium produces three distinct clinical forms of the disease: bubonic plague, septicemic plague, and pneumonic plague. Each form affects a different part of the body, progresses at a different speed, and carries a different risk of death if untreated.
The Three Forms of Plague
Bubonic plague is the most common form. After a flea bite delivers the bacterium into the skin, it travels to nearby lymph nodes and causes them to swell into painful, egg-sized lumps called buboes, typically in the groin, armpit, or neck. Symptoms usually appear two to eight days after exposure and include sudden fever, chills, headache, and extreme fatigue alongside the characteristic swollen nodes.
Septicemic plague occurs when Y. pestis enters or spreads into the bloodstream. It can develop on its own from a flea bite or as a complication of untreated bubonic plague. Early signs include sudden high fever, chills, extreme weakness, stomach pain, diarrhea, and vomiting. As the infection progresses, blood clots form in tiny vessels supplying the fingers, toes, ears, and nose. The tissue dies and turns black, a form of gangrene that gave plague its medieval nickname, the Black Death. Bleeding from the mouth, nose, or under the skin can follow as organs begin to fail.
Pneumonic plague is the rarest and most dangerous form. It strikes the lungs and can develop either from inhaling respiratory droplets from an infected person (primary pneumonic plague) or when bubonic or septicemic plague spreads to the lungs (secondary pneumonic plague). Symptoms include rapidly worsening cough, chest pain, difficulty breathing, and bloody or watery sputum. Without antibiotic treatment, the death rate for pneumonic plague is approximately 98%. Even with treatment, roughly half of patients with primary pneumonic plague die, making speed of diagnosis critical.
How Y. Pestis Spreads
The bacterium cycles naturally among wild rodents and their fleas. Rock squirrels, ground squirrels, prairie dogs, chipmunks, wood rats, mice, voles, and rabbits all serve as hosts. In this natural cycle, Y. pestis circulates at low levels within rodent populations without necessarily killing large numbers of them. These animals and their fleas act as long-term reservoirs, quietly maintaining the pathogen in the environment.
Humans typically get infected when a flea that fed on an infected rodent bites them. Less commonly, infection comes from handling an infected animal or, in the case of pneumonic plague, breathing in droplets coughed out by an infected person or animal. Pneumonic plague is the only form that spreads directly between people, which is why outbreaks of this type raise particular alarm.
Plague occurs in rural and semi-rural areas of the western United States, primarily in semi-arid upland forests and grasslands. Globally, most human cases since the 1990s have occurred in Africa, with additional cases in parts of Asia and South America. The United States averages about seven human cases per year, ranging from zero to seventeen in any given year.
How Y. Pestis Overwhelms the Immune System
What makes Y. pestis so lethal is its ability to shut down the body’s first line of defense. The bacterium carries a specialized molecular syringe, called a type III secretion system, that injects at least six toxic proteins directly into immune cells. These proteins work together to paralyze the immune cells that would normally engulf and destroy invading bacteria.
One of these proteins disables the molecular anchoring system that immune cells use to grab onto bacteria. Another causes immune cells to physically round up and detach from tissue by dismantling their internal scaffolding. The combined effect is that white blood cells lose both the ability to grip the bacterium and the structural integrity needed to swallow it. Strains of Y. pestis that lack even one of these proteins are efficiently destroyed by the immune system, which highlights how essential this sabotage toolkit is to causing disease.
After its initial encounter with immune cells, Y. pestis also coats itself in a protein capsule (the F1 antigen) that further shields it from being engulfed. This layered defense, blocking the immune response from both inside and outside host cells, gives the bacterium time to multiply rapidly and spread through the body before the immune system can mount an effective counterattack.
A Recently Evolved Killer
Y. pestis evolved from a closely related gut pathogen, Yersinia pseudotuberculosis, that causes relatively mild food-borne illness. The transformation into a flea-transmitted, highly lethal pathogen required remarkably few genetic changes: one gene gain and three gene losses.
The gained gene, carried on a small extra loop of DNA the bacterium picked up, produces an enzyme that allows Y. pestis to survive inside the flea gut. Without it, the bacterium is digested along with the flea’s blood meal. The three lost genes all had the same downstream effect: they increased the bacterium’s ability to form sticky biofilms inside the flea’s foregut. These biofilms physically block the flea’s feeding tube, so when the flea tries to feed on its next host, it regurgitates bacteria-laden material into the bite wound. A blocked, starving flea also bites more aggressively and more frequently, increasing the chance of transmission.
A separate gene on another acquired DNA loop produces a surface enzyme that helps Y. pestis invade deeper tissue from the flea bite site. Together, these handful of mutations turned an intestinal pathogen into one capable of riding inside fleas, escaping from skin into lymph nodes, and overwhelming the bloodstream.
Diagnosis and Treatment
Plague is confirmed in the lab by growing Y. pestis from a patient sample (blood, lymph node fluid, or sputum) and verifying the identity of the bacterium with secondary tests such as a phage lysis assay or fluorescent antibody staining. Faster but less definitive results come from PCR testing or detecting the F1 antigen directly in clinical samples. A fourfold rise in antibodies to the F1 antigen between two blood draws taken days apart also confirms infection.
Antibiotics are effective against all three forms of plague, but timing matters enormously. Treatment works best when started within 24 hours of symptom onset, particularly for pneumonic plague. Patients with pneumonic or septicemic plague are typically treated with injectable antibiotics in a hospital, while uncomplicated bubonic plague can sometimes be managed with oral antibiotics. Recovery depends heavily on how quickly treatment begins and which form of plague is involved.
No plague vaccine is currently approved for human use. Several candidates are in development, but standard clinical trials are not ethically possible since researchers cannot deliberately expose people to a potentially fatal infection. Any future vaccine will likely need to be approved under the FDA’s Animal Rule, which allows authorization based on effectiveness demonstrated in multiple animal species rather than in human trials.